

Patent
Attorney's Docket No. 003301-097

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
IAN RICHARD MATTHEWS <i>et al.</i>)	Group Art Unit: 1645
)	
Application No.: 10/717,519)	Examiner: Unassigned
)	
Filed: November 21, 2003)	Confirmation No.: 8404
)	
For: IMMUNOMODULATORY)	
COMPOUNDS)	

SUBMISSION OF CERTIFIED COPY OF PRIORITY DOCUMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The benefit of the filing date of the following prior foreign Patent Applications in the following foreign country is hereby requested, and the right of priority provided in 35 U.S.C. § 119 is hereby claimed:

- (a) Swedish Patent Application No. 0301851-2
Filed: June 25, 2003,
- (b) Swedish Patent Application No. 0301299-4
Filed: May 6, 2003, and
- (c) Swedish Patent Application No. 0203471-8
Filed: November 22, 2002

In support of this claim, enclosed are certified copies of said prior foreign Patent Applications. Said prior foreign Patent Applications are referred to in the oath or declaration. Acknowledgment of receipt of the certified copies is requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: March 18, 2004

By: Benton S. Duffett, Jr.
Benton S. Duffett, Jr.
Registration No. 22,030

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.



(71) *Sökande* *Active Biotech AB, Lund SE*
Applicant (s)

(21) *Patentansökningsnummer* *0301851-2*
Patent application number

(86) *Ingivningsdatum* *2003-06-25*
Date of filing

Stockholm, 2003-11-14

För Patent- och registreringsverket
For the Patent- and Registration Office

Hjördis Segerlund
Hjördis Segerlund

Avgift
Fee *170:-*

AWAPATENT AB

Kontor/Handläggare

Malmö/Kristina Walls/KRA

Active Biotech AB

Ansökningsnr

Vår referens

SE-21004522

1

IMMUNOMODULATORY COMPOUNDS

The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosus and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.


Background of the invention

The immune system possesses the ability to control the homeostasis between the activation and inactivation of lymphocytes through various regulatory mechanisms during and after an immune response. Among these are mechanisms that specifically inhibit and/or turn off an immune response. Thus, when an antigen is presented by MHC molecules to the T-cell receptor, the T-cells become properly activated only in the presence of additional co-stimulatory signals. In the absence of accessory signals there is no lymphocyte activation and either a state of functional inactivation termed anergy or tolerance is induced, or the T-cell is specifically deleted by apoptosis. One such co-stimulatory signal involves interaction of CD80 on specialised antigen-presenting cells with CD28 on T-cells, which has been demonstrated to be essential for full T-cell activation. (Lenschow et al. (1996) *Annu. Rev. Immunol.*, 14, 233-258)


A paper by Erbe et al, in *J. Biol. Chem.* Vol. 277, No. 9, pp 7363-7368, describes three small molecule ligands which bind to CD80, and inhibit binding of CD80 to CD28 and CTLA4. Two of the disclosed ligands are fused pyrazolones of structures A and B:

5

10



A




B

DESCRIPTION OF THE INVENTION

According to the present invention there is provided
a compound of formula (I) or a pharmaceutically or vete-
rinarly acceptable salt thereof:

20



(I)

wherein

25

R_1 and R_3 independently represent H; F; Cl; Br; $-\text{NO}_2$; $-\text{CN}$; $\text{C}_1\text{-C}_6$ alkyl optionally substituted by F or Cl; or $\text{C}_1\text{-C}_6$ alkoxy optionally substituted by F;

R_2 represents H, or optionally substituted $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_7$ cycloalkyl or optionally substituted phenyl;

30

Y represents $-\text{O}-$, $-\text{S}-$, N-oxide, or $-\text{N}(\text{R}_5)-$ wherein R_5 represents H or $\text{C}_1\text{-C}_6$ alkyl;

X represents a bond or a divalent $\text{C}_1\text{-C}_6$ alkylene radical;

R_4 represents $-\text{C}(=\text{O})\text{NR}_6\text{R}_7$, $-\text{NR}_7\text{C}(=\text{O})\text{R}_6$, $-\text{NR}_7\text{C}(=\text{O})\text{OR}_6$, $-\text{NHC}(=\text{O})\text{NHR}_6$, or $-\text{NHC}(=\text{S})\text{NHR}_6$ wherein

35

R_6 represents H, or a radical of formula $-(\text{Alk})_b\text{-Q}$ wherein b is 0 or 1, and

Alk is an optionally substituted divalent straight chain or branched C₁-C₁₂ alkylene radical which may be interrupted by one or more non-adjacent -O-, -S- or -N(R₈)- radicals wherein R₈ represents H or C₁-C₄ alkyl, C₃-C₄ alkenyl, C₃-C₄ alkynyl, or C₃-C₆ cycloalkyl, and

Q represents H; -CF₃; -OH; -SH; -NR₈R₈ wherein each R₈ may be the same or different; an ester group; or an optionally substituted phenyl, C₃-C₇ cycloalkyl, C₅-C₇ cycloalkenyl or heterocyclic ring having from 5 to 8 ring atoms; and

R₇ represents H or C₁-C₆ alkyl; or when taken together with the atom or atoms to which they are attached R₆ and R₇ form a heterocyclic ring having from 5 to 8 ring atoms.

Compounds of general formula (I) are CD80 antagonists. They inhibit the interaction between CD80 and CD28 and thus the activation of T cells, thereby modulating the immune response.

Accordingly the invention also includes:

(i) a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof for use in the treatment of conditions which benefit from immunomodulation.

(ii) the use of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof in the manufacture of a medicament for the treatment of conditions which benefit from immunomodulation.

(iii) a method of immunomodulation in mammals, including humans, comprising administration to a mammal in need of such treatment an immunomodulatory effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof.

(iv) a pharmaceutical or veterinary composition comprising a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof together with a pharmaceutically or veterinarily acceptable excipient or carrier.

Conditions which benefit from immunomodulation include:

- Adrenal insufficiency
- Allergic angiitis and granulomatosis
- 5 Amylodosis
- Ankylosing spondylitis
- Asthma
- Autoimmune Addison's disease
- Autoimmune alopecia
- 10 Autoimmune chronic active hepatitis
- Autoimmune hemolytic anemia
- Autoimmune neutropenia
- Autoimmune thrombocytopenic purpura
- Autoimmune vasculitides
- 15 Behçet's disease
- Cerebellar degeneration
- Chronic active hepatitis
- Chronic inflammatory demyelinating polyradiculoneuropathy
- Dermatitis herpetiformis
- 20 Diabetes
- Eaton-Lambert myasthenic syndrome
- Encephalomyelitis
- Epidermolysis bullosa
- Erythema nodosa
- 25 Gluten-sensitive enteropathy
- Goodpasture's syndrome
- Graft versus host disease
- Guillain-Barre syndrome
- Hashimoto's thyroiditis
- 30 Hyperthyrodism
- Idiopathic hemachromatosis
- Idiopathic membranous glomerulonephritis
- Minimal change renal disease
- Mixed connective tissue disease
- 35 Multifocal motor neuropathy
- Multiple sclerosis
- Myasthenia gravis

- Opsoclonus-myoclonus syndrome
- Pemphigoid
- Pemphigus
- Pernicious anemia
- 5 Polyarteritis nodosa
- Polymyositis/dermatomyositis
- Post-infective arthritides
- Primary biliary sclerosis
- Psoriasis
- 10 Reactive arthritides
- Reiter's disease
- Retinopathy
- Rheumatoid arthritis
- Sclerosing cholangitis
- 15 Sjögren's syndrome
- Stiff-man syndrome
- Subacute thyroiditis
- Systemic lupus erythematosus
- Systemic sclerosis (scleroderma)
- 20 Temporal arteritis
- Thromboangiitis obliterans
- Transplantation rejection
- Type I and type II autoimmune polyglandular syndrome
- Ulcerative colitis
- 25 Uveitis
- Wegener's granulomatosis

As used herein the term "alkylene" refers to a straight or branched alkyl chain having two unsatisfied valencies, for example $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$,

- 30 $-\text{CH}(\text{CH}_3)\text{CH}_2-$, $-\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{CH}_2\text{CH}_3$, and $-\text{C}(\text{CH}_3)_3$.

As used herein the term "heteroaryl" refers to a 5- or 6- membered aromatic ring containing one or more heteroatoms. Illustrative of such groups are thienyl, furyl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thia-

35 diazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl.

As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in particular means a 5-8 membered aromatic or non-aromatic heterocyclic ring containing one or more hetero-
5 atoms selected from S, N and O, including for example, pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzofuranyl, pyranyl,
10 isoxazolyl, quinuclidinyl, aza-bicyclo[3.2.1]octanyl, benzimidazolyl, methylenedioxyphenyl, maleimido and succinimido groups.

Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety
15 herein means substituted with one or more of the following substituents, namely (C₁-C₆)alkyl, trifluoromethyl, (C₁-C₆)alkoxy (including the special case where a ring is substituted on adjacent ring C atoms by methylenedioxy or ethylenedioxy), trifluoromethoxy, (C₁-C₆)alkylthio, phenyl, benzyl, phenoxy, hydroxy, mercapto, amino, fluoro,
20 chloro, bromo, cyano, nitro, oxo, -COOH, -SO₂OH, -CONH₂, -SO₂NH₂, -COR^A, -COOR^A, -SO₂OR^A, -NHCOR^A, -NHSO₂R^A, -CONHR^A, -SO₂NHR^A, -NHR^A, -NR^AR^B, -CONR^AR^B or -SO₂NR^AR^B wherein R^A and R^B are independently a (C₁-C₆)alkyl group. In the case
25 where "substituted" means substituted by, phenyl, benzyl or phenoxy, the phenyl ring thereof may itself be substituted with any of the foregoing, except phenyl or benzyl.

As used herein the unqualified term "carbocyclyl" or "carbocyclic" refers to a 5-8 membered ring whose ring
30 atoms are all carbon.

Some compounds of the invention contain one or more chiral centres because of the presence of asymmetric carbon atoms. The presence of asymmetric carbon atoms gives rise to stereoisomers or diastereoisomers with R or S
35 stereochemistry at each chiral centre. The invention includes all such stereoisomers and diastereoisomers and mixtures thereof.

Salts of salt forming compounds of the invention include physiologically acceptable acid addition salts for example hydrochlorides, hydrobromides, sulphates, methane sulphonates, p-toluenesulphonates, phosphates, acetates, citrates, succinates, lactates, tartrates, fumarates and maleates; and base addition salts, for example sodium, potassium, magnesium, and calcium salts.

In the compounds of the invention the following are examples of the several structural variables:

R_1 may be, for example, H, F, Cl, methyl, methoxy, or methylenedioxy. Currently it is preferred that R_1 is H, F, or Cl;

R_2 may be, for example H, methyl, methoxy, cyclopropyl, phenyl, or fluoro-, chloro-, methyl, or methoxy-substituted phenyl. H or cyclopropyl is presently preferred;

R_3 may be, for example, H, F, Cl, methyl, methoxy, or methylenedioxy. Currently it is preferred that R_3 is H, F, or Cl;

Y may be, for example, -O-, -S-, or -N(R_5)- wherein R_5 represents H or methyl. -NH- is presently preferred.

X may be, for example a bond, or a -CH₂- or -CH₂CH₂- radical. A bond is presently preferred.

R_4 represents -C(=O)NR₆R₇, -NR₇C(=O)R₆, -NR₇C(=O)OR₆ or -NHC(=O)NHR₆ and in these

R_6 may be, for example, H or a radical of formula -Alk_b-Q wherein b is 0 or 1 and



Alk is a -(CH₂)_n-, -CH((CH₂)_mCH₃)(CH₂)_n-, -CH((CH₂)_mCH₃)((CH₂)_pCH₃)(CH₂)_n-, -(CH₂)_n-O-(CH₂)_m-, or -(CH₂)_n-O-(CH₂)_n-O-(CH₂)_m-, radical where n is 1, 2, 3 or 4 and m and p are independently 0, 1, 2, 3 or 4, and

Q represents H, -OH, -COOCH₃, phenyl, cyclopropyl, cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or oxazolyl; and

R_7 may be, for example, H, or when taken together with the atom or atoms to which they are attached R_6 and R_7 may form a heterocyclic ring of 5, 6 or 7 members.



Specific examples of R_4 groups include those present
5 in the compounds of the Examples herein.

Compounds of the invention may be prepared by synthetic methods known in the literature, from compounds which are commercially available or are accessible from commercially available compounds. For example, compounds
10 of formula (I) wherein R_4 is a group $-NR_7C(=O)R_6$ may be prepared by acylation of an amine of formula (II) with an acid chloride of formula (III):




15

Compounds of the invention wherein R_4 is a group $-NHC(=O)NHR_6$ may be prepared by reaction of an amine of formula (IIA) with an isocyanate of formula (IIIA)



Compounds of the invention wherein R_4 is a group $-C(=O)NHR_6$ may be prepared by reaction of an acid chloride of formula (IIB) with an amine NH_2R_6 :



5


Compounds of the invention wherein R_4 is a group $-NR_7C(=O)OR_6$ may be prepared by reaction of an amine of formula (II) with a chloroformate $ClC(=O)OR_6$.

The following Examples illustrate the preparation of compounds of the invention:

Preparation of Intermediate 1

2-(4-Nitrophenyl)-6-fluoro-2,5-dihydropyrazolo[4,3-c]-quinolin-3-one

15




20

4-Nitrophenylhydrazine (2.28 g, 0.014 mol) was added in one portion to a stirred solution of 4-chloro-8-fluoro-quinoline-3-carboxylic acid ethyl ester (3.58 g, 0.014 mol) in anhydrous n-butyl alcohol (50 ml) at room temperature. The mixture was refluxed for 16 h under nitrogen, cooled to room temperature and then filtered to leave an orange solid. The solid was purified by washing sequentially with ethyl acetate (20 ml) and heptane (20 ml) and then finally dried under suction to give the pyrazolone (3.93 g, 87 %) as a dark orange solid, LCMS m/z 325.24 $[M+H]^+$ @ R_T 1.47 min.

Preparation of Intermediate 2


2-(4-Aminophenyl)-6-fluoro-2,5-dihydropyrazolo[4,3-c]-
quinolin-3-one



Tin (II) chloride dihydrate (12.5 g, 0.055 mol) was added in one portion to a stirred solution of 2-(4-nitrophenyl)-6-fluoro-2,5-dihydro-pyrazolo[4,3-c]quinolin-3-one (intermediate 1) (3.59 g, 0.011 mol) in ethyl alcohol (110 ml) at room temperature. The mixture was then heated to 80 °C for 8 h, cooled to room temperature and filtered to leave a yellow solid. The solid was suspended in a biphasic solution of ethyl acetate (1L), a saturated solution of Rochelles salt (500 ml) and a saturated solution of sodium bicarbonate (500 ml) and stirred at room temperature for 2h. The mixture was filtered and the remaining solid was washed with water and dried under vacuum to afford the title compound (3.39 g, 99 %) as a bright yellow solid, LCMS m/z 295.30 [M+H]⁺ @ R_T 0.84 min.

Example 1

N-[4-(6-Fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)-phenyl]-2-methyl-butylamide



(±)-2-Methylbutyryl chloride (13.6 µl, 0.11 mmol) was added dropwise over 30 sec to a stirred solution of 2-(4-amino-phenyl)-6-fluoro-2,5-dihydro-pyrazolo[4,3-


c]quinolin-3-one (Intermediate 2) (30 mg, 0.10 mmol), triethylamine (14 μ l, 0.11 mmol) and 4-dimethylaminopyridine (2.4 mg, 0.02 mmol) in dichloromethane (1 ml) at room temperature. The mixture was stirred at room temperature for 16 h. The yellow solid was then filtered and purified by washing sequentially with a saturated solution of sodium bicarbonate (1 ml), ethyl acetate (1 ml) and ethyl alcohol (0.5 ml) and finally dried under suction to give the title compound (10 mg, 26 %) as a bright yellow solid, LCMS m/z 379.36 $[M+H]^+$ @ R_T 1.18 min. δ_H (400 MHz, $(CD_3)_2SO$) 9.89 (1H, s), 8.52 (1H, s), 8.15 (2H, d J 9.0 Hz), 8.01 (1H, d J 7.0 Hz), 7.69 (2H, d J 9.0 Hz) 7.57-7.46 (2H, m), 2.46-2.39 (1H, m), 1.69-1.36 (2H, m), 1.11 (3H, d J 6.8 Hz), 0.91 (3H, t J 7.3 Hz).

Examples 2-28

The following compounds were synthesized by the route described in Example 1, substituting the appropriate acid chloride for (\pm)-2-methylbutyryl chloride:

Example 2

2-Methyl-pentanoic acid [4-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-phenyl]-amide



25

δ_H (400 MHz, $(CD_3)_2SO$) 9.92 (1H, s), 8.53 (1H, s), 8.12 (2H, d J 9.2 Hz), 8.05 (1H, d J 7.6 Hz), 7.70 (2H, d J 9.2 Hz), 7.63-7.53 (2H, m), 1.68-1.58 (1H, m), 1.38-1.28 (3H, m), 1.11 (3H, d J 6.6 Hz), 0.91 (3H, t J 7.1 Hz).


30

Example 3

1-Methyl-1H-pyrrole-2-carboxylic acid [4-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-phenyl]-amide

35

12




5

δ_H (400 MHz, $(CD_3)_2SO$) 9.76 (1H, s), 8.50 (1H, s),
 8.26 (2H, d 9.0 Hz), 7.97-7.94 (1H, m), 7.73 (2H, d J 9.0
 10 Hz), 7.39-7.28 (2H, m), 7.07-7.01 (2H, m), 3.91 (3H, s).

Example 4

N-[4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-
 2-yl)-phenyl]-3-methyl-butylamide

15




20

δ_H (400 MHz, $(CD_3)_2SO$) 9.92 (1H, s), 8.52 (1H, s),
 8.14 (2H, d J 9.2 Hz), 8.01 (1H, d J 7.3 Hz), 7.67 (2H,
 d J 9.2 Hz), 7.57-7.47 (2H, m), 2.21 (2H, d J 6.8 Hz),
 25 2.14-2.07 (1H, m), 0.96 (6H, d J 6.6 Hz).

Example 5

2-Propyl-pentanoic acid [4-(6-fluoro-3-oxo-3,5-dihydro-
 pyrazolo[4,3-c]quinolin-2-yl)-phenyl]-amide

30



35


13

δ_H (400 MHz, $(CD_3)_2SO$) 9.93 (1H, s), 8.53 (1H, s), 8.11 (2H, d J 9.0 Hz), 8.05 (1H, d J 7.8 Hz), 7.70 (2H, d J 9.0 Hz), 7.59-7.46 (2H, m), 2.46-2.35 (1H, m), 1.63-1.27 (4H, m), 0.90 (6H, t J 7.1 Hz).

5 Example 6

5-[4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl) phenylcarbamoyl]-pentanoic acid methyl ester

10



15


δ_H (400 MHz, $(CD_3)_2SO$) 9.85 (1H, s), 8.47 (1H, s), 8.25 (2H, d J 9.0 Hz), 7.91-7.90 (1H, m), 7.59 (2H, d J 9.0 Hz), 7.29-7.20 (2H, m), 3.61 (3H, s), 2.38-2.28 (4H, m), 1.64-1.50 (4H, m).

20

Example 7

N-[4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-phenyl]-2,2-dimethyl-propionamide

25




30

δ_H (400 MHz, $(CD_3)_2SO$) 9.26 (1H, s), 8.52 (1H, s), 8.15 (2H, d J 9.2 Hz), 8.03 (1H, d J 8.8 Hz), 7.71 (2H, d J 9.2 Hz), 7.56-7.47 (2H, m), 1.26 (9H, s).

Examples 8 to 28 were also prepared by the method of







35 Example 1 using the appropriate acid chloride:

5




R	m/z [M+H] ⁺	LC min	R	m/z [M+H] ⁺	LC min	R	m/z [M+H] ⁺	LC min
Ex8 	443.43	1.31	Ex9 	371.31	1.09	Ex10 	389.34	1.12
 Ex11	485.45	0.98	 Ex12	381.34	1.08	Ex13 Ex13	367.18	1.15
 Ex14	507.43	1.41	Ex15 Ex15	466.41	1.43	Ex16 Ex16	337.36	0.98
Ex17 	421.46	1.41	Ex18 	393.41	1.24	Ex19 	405.41	1.28
 Ex20	448.44	0.96	Ex21 Ex21	481.35	1.35	Ex22 Ex22	423.42	1.11

15

 Ex23	493.51	1.37	 Ex24	365.36	1.09	 Ex25	411.40	1.05
 Ex 26	393.46	1.11	 Ex27	367.24	1.04	 28	390.33	1.09

Example 29

{3-[4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quino-
5 lin-2-yl)-phenyl]-ureido} acetic acid ethyl ester




10

Ethyl cyanatoacetate (31 mg, 0.24 mmol) was added in one portion to a stirred solution of 2-(4-aminophenyl)-6-fluoro-2,5-dihydropyrazolo[4,3-c]quinolin-3-one (intermediate 2) (50 mg, 0.17 mmol) in *N,N*-dimethylformamide (2 ml) and the mixture stirred at room temperature for 16 h. Water (1 ml) was then added to the mixture to precipitate a solid, which was filtered, washed with water (1 ml) and then ethyl acetate (1 ml) and finally dried by suction to leave the urea as a yellow solid, LCMS *m/z* 424.40 [M+H]⁺ @ *R_T* 1.06 min.


20

Examples 30 and 31

The following compounds were synthesised by the method of Example 29, substituting the appropriate isocyanate for ethyl cyanatoacetate.




Example 30
LCMS m/z 438.41 [M+H]⁺ @ RT 1.13 min.



Example 31
LCMS m/z 514.46 [M+H]⁺ @ RT 1.35 min

Preparation of Intermediate 3

3-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid



10


3-Hydrazinobenzoic acid (1.91 g, 0.013 mol) was added in one portion to a stirred solution of 4-chloro-8-fluoro-quinoline-3-carboxylic acid ethyl ester (2.93 g, 0.011 mol) in n-butanol (60 ml) at room temperature. The solution was heated to reflux for 16 h, cooled to room temperature and the resulting yellow solid filtered, washed with tert-butyl methyl ether and then dried. The solid was redissolved in a solution of tetrahydrofuran : water (2:1; 21 ml) and lithium hydroxide (1.27 g, 0.031 mol) was then added. After stirring at room temperature for 16 h, concentrated hydrochloric acid (3 ml) was added dropwise to the mixture to precipitate a yellow solid which was filtered and dried under vacuum to give the title compound (intermediate 3) (2.32 g, 63 %) as a bright yellow solid.

25

Preparation of Intermediate 4

3-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoyl chloride

5




Oxalyl chloride (20 ml, 0.2 mol) was added dropwise
10 over 2 min to a stirred solution of 3-(6-fluoro-3-oxo-
3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid
(intermediate 3) (2.0 g, 6.1 mmol) in dichloromethane (10
ml) at room temperature. *N,N*-Dimethylformamide (50 μ l)
was then added and the resulting mixture heated to 50 °C
15 for 1 h. The solution was then cooled to room temperature
and then concentrated in vacuo to leave the title
compound (intermediate 4) (2.0 g, 96 %) as a beige solid.

Example 32

3-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-
20 N-(3-methoxy-propyl)-benzamide

25




3-Methoxypropylamine (0.026g, 0.29mmol) was added to
a stirred solution of 3-(6-fluoro-3-oxo-3,5-dihydro-
pyrazolo[4,3-c]quinolin-2-yl)-benzoyl chloride (interme-
30 diate 4) (26 mg 0.29mmol) in tetrahydrofuran (2 ml) and
the mixture stirred at room temperature for 15 min. Tri-
ethylamine (0.2 ml, 1.4 mmol) was then added and the re-
sulting mixture stirred overnight. 1M Hydrochloric acid
(3-4 ml) was added dropwise to precipitate a yellow solid
35 which was filtered and dried under suction to give the
amide (79 mg, 0.20 mmol) as a yellow solid, LCMS m/z
395.25 [M+H]⁺ @ R_T 1.04 min; δ_H (400 MHz, (CD₃)₂SO) 8.59

18

(1H, m), 8.57 (1H, s), 8.39 (1H, app d J 9.3 Hz), 8.08 (1H, app d J 7.3 Hz), 7.66-7.53 (5H, m), 3.37-3.33 (4H, m), 3.27 (3H, s), 1.83-1.77 (2H, m).

Example 33

- 5 N-Ethyl-3-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]-quinolin-2-yl)-benzamide




10

Prepared by the method of Example 32 substituting ethylamine for 3-methoxypropylamine.

- 15 δ_H (400 MHz, $(CD_3)_2SO$) major rotomer quoted; 8.56 (1H, br s), 8.47 (1H, m), 8.21 (2H, d J 8.5 Hz), 7.94 (2H, d J 8.5 Hz), 3.96 (3H, s), 3.31 (2H, q J 7.3 Hz), 2.58 (3H, s), 1.15 (3H, t J 7.4 Hz).

Example 34

- 20 N-Benzyl-3-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]-quinolin-2-yl)-benzamide



25

Prepared by the method of Example 32 substituting benzylamine for 3-methoxypropylamine.


LCMS m/z 427.16 $[M+H]^+$ @ R_T 1.28 min.

- 30 Example 35

N-(3-Dimethylamino propyl)-4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzamide

Step 1

- 2-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester
- 35




A solution of 3-cyclopropyl-3-oxo-propionic acid methyl ester (6.2 g, 0.038 mols), 2-amino benzoic acid ethyl ester (4.95 g, 0.03 mols) and *p*-toluene sulfonic acid (0.04 g, 0.2 mmols) in toluene (25 ml) was heated at 125°C for 2h; 15 ml of solvent was then distilled. To the residual orange solution was added sodium ethoxide (2 M, 15 ml) in ethanol (reaction mixture turns red). This red mixture was stirred at 120°C for 2 h; 15 ml of solvent was again distilled. The reaction mixture was left to cool to room temperature, diluted with ethyl acetate (1 litre), extracted with HCl 0.1 M and water. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo to leave an orange residue which was washed once with cold ethyl acetate to yield 2-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester (3.87 g, 53%) as an off-white solid. LCMS *m/z* 244.14 [M+H]⁺ @ *R_T* 0.78 min, 89%, *m/z* 230.11 [Acid+H]⁺ @ *R_T* 1.27, 11%.

δ_H (400 MHz, (CD₃)₂SO) 11.04 (1 H, s), 8.06 (1 H, dd, *J*₁ 1.1, *J*₂ 8.1), 7.76-7.66 (2 H, m), 7.36 (1 H, td, *J*₁ 1.1, *J*₂ 7.5), 3.89 (3 H, s), 2.16 (1 H, m), 1.18 (4 H, d, *J* 7.0).

Step 2


4-Chloro-2-cyclopropyl-quinoline-3-carboxylic acid ethyl ester



Phosphorus oxychloride (0.77 ml, 0.082 mols) was added in one portion to a suspension of 2-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester (1.0 g, 0.041 mols) in acetonitrile and the mixture was heated at 75°C for 90 minutes (becomes a clear solution above 65°C). The resulting light brown solution was poured into saturated sodium bicarbonate (100 ml); the suspension was extracted with ethyl acetate and the combined organic extracts were dried and concentrated in vacuo to leave 4-Chloro-2-cyclopropyl-quinoline-3-carboxylic acid ethyl ester (1.15 g, 106 %) as an off-white solid. R_f (AcOEt) = 0.73.

15 **Step 3**

4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid



20

4-Chloro-2-cyclopropyl-quinoline-3-carboxylic acid ethyl ester (1.15 g, 0.0041 mols) and 4-hydrazino-benzoic acid (1.0g, 0.0068 mols) were stirred in ethanol (30 ml) at reflux for 16 h. The bright yellow suspension was diluted with heptane, filtered, washed with cold t-butylmethyl ether and left to dry under suction to yield crude solid

25


21

containing hydrazine. This solid was suspended in 1 M HCl, filtered, washed with water and then dried in vacuo to yield 4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid (1.135 g, 80 %) as a yellow solid, LCMS m/z 346.20 [M+H]⁺ @ R_T 1.05 min: 96% purity.

δ_H (400 MHz, (CD₃)₂SO) 11.4 (1 H, s), 8.43 (2 H, d, *J* 8.1), 8.21 (1 H, dd, *J*₁ 1.2, *J*₂ 8.1), 8.07 (2 H, d, *J* 8.1), 7.92 (1 H, d, *J* 8.1), 7.67 (1 H, t, *J* 6.6), 7.52 (1 H, t, *J* 6.5), 3.43 (1 H, m), 1.59 (2 H, m), 1.43 (2 H, m).

Step 4

4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]-quinolin-2-yl)-benzoyl chloride




To a suspension of finely ground 4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid (0.19 g, 0.55 mmol) in dichloromethane (4 ml) was added oxalyl chloride (1.6 ml, 0.01 mol) followed by a drop of dimethyl formamide. The mixture was stirred under nitrogen at 45 °C for 8 h. The solvent was removed in vacuo to yield 4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoyl chloride as a pale yellow solid, LCMS m/z [M+MeOH-Cl]⁺ @ R_T 1.46 min: 95% purity. Used without further purification.

Step 5

N-(3-Dimethylamino propyl)-4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzamide


5



To a partial solution of 4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoyl chloride
10 (0.1 g, 0.28 mmol) in tetrahydrofuran (6 ml) under nitrogen was added a solution of 3-dimethylamino-propyl amine (0.03 g, 0.3 mmol) in tetrahydrofuran (3 ml). The mixture was stirred at RT for 3 h. The solvent was removed under reduced pressure and the yellow solid was washed with a little saturated sodium bicarbonate, water
15 and dried under vacuo to yield N-(3-Dimethylamino propyl)-4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzamide (57 mg, 47 %) as a yellow solid. LCMS m/z 430.11 [M+H]⁺ @ R_T 0.99 min: 100% purity.

20 **Preparation of Intermediate 5**

4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoyl chloride




To a suspension of finely ground 4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid (1.1
 5 g. 3.4 mmol) in dichloromethane (6 ml) was added oxalyl chloride (2.4 ml, 29 mmol) followed by a drop of dimethyl formamide. The mixture was stirred under nitrogen at 45 °C for 3 h. The solvent was removed in vacuum to yield 4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoyl chloride (1.15 g, quantitative) as a pale
 10 yellow solid that was used without further purification.

Example 36

N-(3-Dimethylamino propyl)-4-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzamide hydrochloride

15




To a partial solution of 4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoyl chloride (0.1 g,
 20 0.3 mmol) in tetrahydrofuran (5 ml) under nitrogen was added a solution of 3-dimethylamino-propyl amine (0.03 g, 0.3 mmol) in tetrahydrofuran. The mixture was stirred at rt for 90 minutes. The solvent was removed under

reduced pressure and the yellow solid was purified via FCC silica gel (gradient elution, MeOH:H₂O, Fluka C₁₈ reverse phase) to yield *N*-(3-Dimethylamino propyl)-4-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-*c*]quinolin-2-yl)-benzamide hydrochloride (70 mg, 53 %) as a yellow solid.













LCMS *m/z* 408.39 [M+H]⁺ @ R_T 0.89 min: 90% purity.

Exmaples 37 - 114 were prepared analogolously from 4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-*c*]quinolin-2-yl)-benzoyl chloride and the appropriate amine
















Example	X	Z	W	R	R'	M.S. (MH ⁺)
37	6-F	H	H	-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ -		391.3
38	6-F	H	H	-CH ₂ Phenyl	H	413.2
39	6-F	H	H	-CH ₂ Phenyl	Me	427.3
40	6-F	H	H	-CH ₂ CH ₂ OMe	H	381.2
41	6-F	H	H	-CH ₂ CH ₂ N(Me) ₂	H	394.3
42	6-F	H	H	-CCMe	H	395.3
43	6-F	H	H	-CCCOMe	H	395.2
44	6-F	H	H	-CCCN(Me) ₂	H	408.3
45	6-F	H	H		H	431.3
46	6-F	H	H		H	419.2
47	6-F	H	H	Et	H	351.2
48	6-F	H	H	Et	Et	379.3
49	6-F	H	H		H	420.4
50	6-F	H	H	-CH ₂ CH ₂ CH ₂ N(Me) ₂	Me	422.4














25

51	6-F	H	H	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	422.4
52	6-F	H	H		H	448.5
53	6-F	H	H		H	434.4
54	6-F	H	H		H	525.3
55	6-F	H	H	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	450.3
56	H	H	H	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	390.2
57	H	H	H	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	432.1
58	H	H	H	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Et})_2$	H	432.2
59	H	H	H	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	Me	404.2
60	6-F	H	2-Cl	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	442.05
61	H	H	H		H	416.1
62	H	H	H		H	573.03
63	H	H	H		H	445.1
64	H	H	H		H	507.1
65	6-F	H	H		H	591.02
66	H		H	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	430.1
67	6-F	H	H		H	464.1
68	6-F	H	H		H	463.1
69	6-F	H	3-Cl		H	482.05






















1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100

26



70	6-F	H	2-Cl		H	497.1
71	6-F	H	2-Cl	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Et})_2$	H	484.09
72	6-F	H	2-Cl	 $-\text{CH}_2\text{CH}_2\text{N}(\text{Et})_2$		580.5
73	6-F	H	3-Cl	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	442.06
74	H		H		H	470.4
75	6-F	H	H			516.3
76	6-F	H	H		H	470.3
77	6-F	H	H	$-\text{CH}_2\text{CH}_2\text{N}(\text{iPr})_2$	H	451.4
78	6-F	H	2-Cl		H	496.2
79	6-F	H	H		H	456.1
80	6-F	H	2-Cl	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	456.1
81	6-F	H	H			406.2
82	6-F	H	H		H	462.1
83	6-F	H	H		H	436.1
84	6-F	H	H		H	434.4
85	6-F	H	H		H	476.1

86	6-F	H	H		H	496.1
87	6-F	H	H		H	436.3
88	6-F	H	H		H	462.33
89	6-F	H	H	 -CH ₂ CH ₂ N(Et) ₂		546.1
90	6-F	H	H		H	428.1
91	6-F	H	H	-CH ₂ CH ₂ SEt	H	411.3
92	6-F	H	H		H	448.3
93	6-F	H	H		H	431.3
94	6-F	H	H		H	434.3
95	6-F	H	H	-CH ₂ CH ₂ CH ₂ CH ₂ N(Et) ₂	H	450.4
96	6-F		H		H	536.1
97	6-F		H		H	516.2
98	6-F	H	H		H	428.3
99	6-F	H	H	-CH ₂ CH ₂ CH ₂ SMe	H	411.3

28

100	H		H		H	498.5
101	6-F		H		H	488.4
102	6-F	H	H		H	446.3
103	6-F		H	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	448.2
104	6-F		H		H	502.3
105	6-F		H		H	486.3
106	6-F		H	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Et})_2$	H	490.3
107	6-F		H		H	546.2
108	6-F		H		H	631.2
109	6-F		H		H	468.2
110	6-F		H		H	468.2
111	6-F		H		H	476.2

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606
 607
 608
 609
 610
 611
 612
 613
 614
 615
 616
 617
 618
 619
 620
 621
 622
 623
 624
 625
 626
 627
 628
 629
 630
 631
 632
 633
 634
 635
 636
 637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
 650
 651
 652
 653
 654
 655
 656
 657
 658
 659
 660
 661
 662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675
 676
 677
 678
 679
 680
 681
 682
 683
 684
 685
 686
 687
 688
 689
 690
 691
 692
 693
 694
 695
 696
 697
 698
 699
 700
 701
 702
 703
 704
 705
 706
 707
 708
 709
 710
 711
 712
 713
 714
 715
 716
 717
 718
 719
 720
 721
 722
 723
 724
 725
 726
 727
 728
 729
 730
 731
 732
 733
 734
 735
 736
 737
 738
 739
 740
 741
 742
 743
 744
 745
 746
 747
 748
 749
 750
 751
 752
 753
 754
 755
 756
 757
 758
 759
 760
 761
 762
 763
 764
 765
 766
 767
 768
 769
 770
 771
 772
 773
 774
 775
 776
 777
 778
 779
 780
 781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796
 797
 798
 799
 800
 801
 802
 803
 804
 805
 806
 807
 808
 809
 810
 811
 812
 813
 814
 815
 816
 817
 818
 819
 820
 821
 822
 823
 824
 825
 826
 827
 828
 829
 830
 831
 832
 833
 834
 835
 836
 837
 838
 839
 840
 841
 842
 843
 844
 845
 846
 847
 848
 849
 850
 851
 852
 853
 854
 855
 856
 857
 858
 859
 860
 861
 862
 863
 864
 865
 866
 867
 868
 869
 870
 871
 872
 873
 874
 875
 876
 877
 878
 879
 880
 881
 882
 883
 884
 885
 886
 887
 888
 889
 890
 891
 892
 893
 894
 895
 896
 897
 898
 899
 900
 901
 902
 903
 904
 905
 906
 907
 908
 909
 910
 911
 912
 913
 914
 915
 916
 917
 918
 919
 920
 921
 922
 923
 924
 925
 926
 927
 928
 929
 930
 931
 932
 933
 934
 935
 936
 937
 938
 939
 940
 941
 942
 943
 944
 945
 946
 947
 948
 949
 950
 951
 952
 953
 954
 955
 956
 957
 958
 959
 960
 961
 962
 963
 964
 965
 966
 967
 968
 969
 970
 971
 972
 973
 974
 975
 976
 977
 978
 979
 980
 981
 982
 983
 984
 985
 986
 987
 988
 989
 990
 991
 992
 993
 994
 995
 996
 997
 998
 999
 1000
 1001
 1002
 1003
 1004
 1005
 1006
 1007
 1008
 1009
 1010
 1011
 1012
 1013
 1014
 1015
 1016
 1017
 1018
 1019
 1020
 1021
 1022
 1023
 1024
 1025
 1026
 1027
 1028
 1029
 1030
 1031
 1032
 1033
 1034
 1035
 1036
 1037
 1038
 1039
 1040
 1041
 1042
 1043
 1044
 1045
 1046
 1047
 1048
 1049
 1050
 1051
 1052
 1053
 1054
 1055
 1056
 1057
 1058
 1059
 1060
 1061
 1062
 1063
 1064
 1065
 1066
 1067
 1068
 1069
 1070
 1071
 1072
 1073
 1074
 1075
 1076
 1077
 1078
 1079
 1080
 1081
 1082
 1083
 1084
 1085
 1086
 1087
 1088
 1089
 1090
 1091
 1092
 1093
 1094
 1095
 1096
 1097
 1098
 1099
 1100
 1101
 1102
 1103
 1104
 1105
 1106
 1107
 1108
 1109
 1110
 1111
 1112
 1113
 1114
 1115
 1116
 1117
 1118
 1119
 1120
 1121
 1122
 1123
 1124
 1125
 1126
 1127
 1128
 1129
 1130
 1131
 1132
 1133
 1134
 1135
 1136
 1137
 1138
 1139
 1140
 1141
 1142
 1143
 1144
 1145
 1146
 1147
 1148
 1149
 1150
 1151
 1152
 1153
 1154
 1155
 1156
 1157
 1158
 1159
 1160
 1161
 1162
 1163
 1164
 1165
 1166
 1167
 1168
 1169
 1170
 1171
 1172
 1173
 1174
 1175
 1176
 1177
 1178
 1179
 1180
 1181
 1182
 1183
 1184
 1185
 1186
 1187
 1188
 1189
 1190
 1191
 1192
 1193
 1194
 1195
 1196
 1197
 1198
 1199
 1200
 1201
 1202
 1203
 1204
 1205
 1206
 1207
 1208
 1209
 1210
 1211
 1212
 1213
 1214
 1215
 1216
 1217
 1218
 1219
 1220
 1221
 1222
 1223
 1224
 1225
 1226
 1227
 1228
 1229
 1230
 1231
 1232
 1233
 1234
 1235
 1236
 1237
 1238
 1239
 1240
 1241
 1242
 1243
 1244
 1245
 1246
 1247
 1248
 1249
 1250
 1251
 1252
 1253
 1254
 1255
 1256
 1257
 1258
 1259
 1260
 1261
 1262
 1263
 1264
 1265
 1266
 1267
 1268
 1269
 1270
 1271
 1272
 1273
 1274
 1275
 1276
 1277
 1278
 1279
 1280
 1281
 1282
 1283
 1284
 1285
 1286
 1287
 1288
 1289
 1290

112	6-F		H		H	474.3
-----	-----	---	---	---	---	-------

Biological Example

The examples described above were tested in a cell free Homogenous Time Resolved Fluorescence (HTRF) assay to determine their activity as inhibitors of the CD80-CD28 interaction.

In the assay, europium and allophycocyanin (APC) are associated with CD28 and CD80 indirectly (through antibody linkers) to form a complex, which brings the europium and APC into close proximity to generate a signal. The complex comprises the following six proteins: fluorescent label 1, linker antibody 1, CD28 fusion protein, CD80 fusion protein, linker antibody 2, and fluorescent label 2. The table below describes these reagents in greater detail.

Fluorescent label 1	Anti-Rabbit IgG labelled with Europium (1µg/ml)
Linker antibody 1	Rabbit IgG specific for mouse Fc fragment (3µg/ml)
CD28 fusion protein	CD28 - mouse Fc fragment fusion protein (0.48µg/ml)
CD80 fusion protein	CD80 mouse Fab fragment (C215) fusion protein (1.9µg/ml)
Linker antibody 2	αMκ-biotin: biotinylated goat IgG specific for mouse kappa chain (2µg/ml)
Fluorescent label 2	SA-APC: streptavidin labelled allophycocyanin (8µg/ml)

On formation of the complex, europium and APC are brought into proximity and a signal is generated.

Non-specific interaction was measured by substituting a mouse Fab fragment (C215) for the CD80 mouse Fab fragment fusion protein (1.9µg/ml). The assay was carried out in black 384 well plates in a final volume of 30µl.


By way of illustration, the EC₅₀ results for the compounds of Examples 15, 21, 29, 35 and 83 were 8 μM, 1.9 μM, 950 nM, 148nM and 90nM respectively.

CLAIMS

1. A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:

5

10



wherein

R_1 and R_3 independently represent H; F; Cl; Br; $-NO_2$; $-CN$; C_1-C_6 alkyl optionally substituted by F or Cl; or C_1-C_6 alkoxy optionally substituted by F;

R_2 represents H, or optionally substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl or optionally substituted phenyl;

Y represents $-O-$, $-S-$, N-oxide, or $-N(R_5)-$ wherein R_5 represents H or C_1-C_6 alkyl;

X represents a bond or a divalent C_1-C_6 alkylene radical;

R_4 represents $-C(=O)NR_6R_7$, $-NR_7C(=O)R_6$, $-NR_7C(=O)OR_6$, $-NHC(=O)NHR_6$ or $-NHC(=S)NHR_6$ wherein

R_6 represents H, or a radical of formula $-(Alk)_b-Q$ wherein b is 0 or 1 and

Alk is an optionally substituted divalent straight chain or branched C_1-C_{12} alkylene radical which may be interrupted by one or more non-adjacent $-O-$, $-S-$ or $-N(R_8)-$ radicals wherein R_8 represents H or C_1-C_4 alkyl, C_3-C_4 alkenyl, C_3-C_4 alkynyl, or C_3-C_6 cycloalkyl, and

Q represents H; $-CF_3$; $-OH$; $-SH$; $-NR_8R_8$ wherein each R_8 may be the same or different; an ester group; or an optionally substituted phenyl, C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or heterocyclic ring having from 5 to 8 ring atoms; and

R_7 represents H or C_1 - C_6 alkyl; or when taken together with the atom or atoms to which they are attached R_6 and R_7 form a heterocyclic ring having from 5 to 8 ring atoms.

5 2. A compound as claimed in claim 1 wherein R_1 is H, F, Cl, methyl or methoxy.

3. A compound as claimed in claim 1 or claim 2 wherein R_2 is H, methyl, methoxy, cyclopropyl, phenyl, or fluoro-, chloro-, methyl, or methoxy-substituted phenyl.

10 4. A compound as claimed in any of the preceding claims wherein R_3 is H, F, Cl, methyl, methoxy, or methylenedioxy.

5. A compound as claimed in any of the preceding claims wherein Y is -O-, -S-, or -N(R_5)- wherein R_5 represents H or methyl.

6. A compound as claimed in any of the preceding claims wherein X is a bond, or a - CH_2 - or - CH_2CH_2 - radical.

7. A compound as claimed in any of the preceding claims wherein R_4 represents -C(=O)NHR₆, -NR₇C(=O)R₆, -NR₇C(=O)OR₆, -NHC(=O)NHR₆ or -NHC(=S)NHR₆ and in these R_6 is H or a radical of formula -Alk_b-Q wherein

b is 0 or 1 and

Alk is a - $(CH_2)_n$ -, -CH((CH₂)_mCH₃)(CH₂)_n-,
25 -CH((CH₂)_mCH₃)((CH₂)_pCH₃)(CH₂)_n-, - $(CH_2)_n$ -O-(CH₂)_m-,
or - $(CH_2)_n$ -O-(CH₂)_n-O-(CH₂)_m-, radical where n is 1, 2, 3
or 4 and m and p are independently 0, 1, 2, 3 or 4, and
Q represents H, -OH, -COOCH₃, phenyl, cyclopropyl,
cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or
30 oxazolyl. and

R_7 is H, or when taken together with the nitrogen atom to which they are attached R_6 and R_7 form a pyrrolidine-2-one or pyrrolidine-2,5-dione ring.

8. A compound as claimed in claim 1 wherein R_1 is
35 H, F, or Cl; R_2 is H; R_3 is H, F, or Cl; Y is -NH-; X is a bond; and R_4 represents -C(=O)NHR₆, -NR₇C(=O)R₆,
-NR₇C(=O)OR₆ or -NHC(=O)NHR₆ wherein:

R_6 is H or a radical of formula $-Alk_b-Q$ wherein

b is 0 or 1 and

Alk is a $-(CH_2)_n-$, $-CH((CH_2)_mCH_3)(CH_2)_n-$,

$-CH((CH_2)_mCH_3)((CH_2)_pCH_3)(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_m-$,

5 or $-(CH_2)_n-O-(CH_2)_n-O-(CH_2)_m-$, radical where n is 1, 2, 3

or 4 and m and p are independently 0, 1, 2, 3 or 4, and

Q represents H, $-OH$, $-COOCH_3$ phenyl, cyclopropyl, cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or oxazolyl. and

10 R_7 is H, or when taken together with the nitrogen atom to which they are attached R_6 and R_7 form a pyrrolidine-2-one or pyrrolidine-2,5-dione ring.

9. N-(3-Dimethylamino propyl)-4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzamide,
15 or pharmaceutically or veterinarily acceptable salt thereof.

10. A compound as claimed in any of claims 1 to 9 for use in the treatment of conditions which benefit from immunomodulation.

20 11. The use of a compound as claimed in any of claims 1 to 9 in the manufacture of a medicament for the treatment of conditions which benefit from immunomodulation.

25 12. A method of immunomodulation in mammals, including humans, comprising administration to a mammal in need of such treatment an immunomodulatory effective dose of a compound as claimed in any of claims 1 to 9.

30 13. A pharmaceutical or veterinary composition comprising a compound as claimed in any of claims 1 to 9 together with a pharmaceutically or veterinarily acceptable excipient or carrier.

ABSTRACT

The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosus and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.

15
16
17
18
19
20
21
22
23
24
25